236 related articles for article (PubMed ID: 33151368)
21. Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus.
Uotani K; Tazawa H; Hasei J; Fujiwara T; Yoshida A; Yamakawa Y; Omori T; Sugiu K; Komatsubara T; Kondo H; Morita T; Kiyono M; Yokoo S; Hata T; Kunisada T; Takeda K; Urata Y; Fujiwara T; Ozaki T
PLoS One; 2024; 19(2):e0298292. PubMed ID: 38377118
[TBL] [Abstract][Full Text] [Related]
22. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.
Kuroda S; Fujiwara T; Shirakawa Y; Yamasaki Y; Yano S; Uno F; Tazawa H; Hashimoto Y; Watanabe Y; Noma K; Urata Y; Kagawa S; Fujiwara T
Cancer Res; 2010 Nov; 70(22):9339-48. PubMed ID: 21045143
[TBL] [Abstract][Full Text] [Related]
23. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.
Huang P; Kaku H; Chen J; Kashiwakura Y; Saika T; Nasu Y; Urata Y; Fujiwara T; Watanabe M; Kumon H
Cancer Gene Ther; 2010 Jul; 17(7):484-91. PubMed ID: 20168351
[TBL] [Abstract][Full Text] [Related]
24. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
26. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
Chen D; Huang L; Zhou H; Zhang Y
Front Immunol; 2021; 12():615089. PubMed ID: 33717103
[TBL] [Abstract][Full Text] [Related]
27. [Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer].
Hashimoto M; Kuroda S; Kanaya N; Kakiuchi Y; Kikuchi S; Tazawa H; Kagawa S; Urata Y; Fujiwara T
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1127-1129. PubMed ID: 36281608
[TBL] [Abstract][Full Text] [Related]
28. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
29. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8
Zhang H; Zhang Y; Dong J; Zuo S; Meng G; Wu J; Wei J
Cell Oncol (Dordr); 2021 Dec; 44(6):1243-1255. PubMed ID: 34491549
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
[TBL] [Abstract][Full Text] [Related]
31. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
32. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
33. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
[TBL] [Abstract][Full Text] [Related]
34. Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial.
Heo J; Liang JD; Kim CW; Woo HY; Shih IL; Su TH; Lin ZZ; Yoo SY; Chang S; Urata Y; Chen PJ
Mol Ther; 2023 Jul; 31(7):2077-2088. PubMed ID: 37060176
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
[TBL] [Abstract][Full Text] [Related]
36. The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment.
Hashimoto Y; Tazawa H; Teraishi F; Kojima T; Watanabe Y; Uno F; Yano S; Urata Y; Kagawa S; Fujiwara T
PLoS One; 2012; 7(6):e39292. PubMed ID: 22720091
[TBL] [Abstract][Full Text] [Related]
37. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
Jhawar SR; Wang SJ; Thandoni A; Bommareddy PK; Newman JH; Marzo AL; Kuzel TM; Gupta V; Reiser J; Daniels P; Schiff D; Mitchell D; LeBoeuf NR; Simmons C; Goyal S; Lasfar A; Guevara-Patino JA; Haffty BG; Kaufman HL; Silk AW; Zloza A; Giurini EF
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433716
[TBL] [Abstract][Full Text] [Related]
38. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
Yano S; Tazawa H; Kishimoto H; Kagawa S; Fujiwara T; Hoffman RM
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477279
[TBL] [Abstract][Full Text] [Related]
39. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
[TBL] [Abstract][Full Text] [Related]
40. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus.
Hashimoto M; Kuroda S; Kanaya N; Kadowaki D; Yoshida Y; Sakamoto M; Hamada Y; Sugimoto R; Yagi C; Ohtani T; Kumon K; Kakiuchi Y; Yasui K; Kikuchi S; Yoshida R; Tazawa H; Kagawa S; Yagi T; Urata Y; Fujiwara T
Br J Cancer; 2024 Apr; 130(7):1187-1195. PubMed ID: 38316993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
